BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36605194)

  • 1. Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells.
    Gazzano M; Parizot C; Psimaras D; Vozy A; Baron M; Abbar B; Fallet V; Litvinova E; Canellas A; Birzu C; Pourcher V; Touat M; Weiss N; Demeret S; Roos-Weil D; Spano JP; Lebbe C; Salem JE; Cadranel J; Hervier B; Gorochov G; Guihot A
    Front Immunol; 2022; 13():1082084. PubMed ID: 36605194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
    van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
    Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
    Das S; Johnson DB
    J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
    Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8673-8680. PubMed ID: 37115270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
    BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
    Kim KH; Hur JY; Cho J; Ku BM; Koh J; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
    Oncoimmunology; 2020; 9(1):1722023. PubMed ID: 32076579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
    Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
    Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
    Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
    J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.